



#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Michael SCHIRNER et al.

Serial No.: 10/088,866

Group Art Unit: 1641

Filed: July 2, 2002

Examiner: UNASSIGNED

For: ANTIBODY-DYE CONJUGATES FOR BINDING TO TARGET STRUCTURES OF  
ANGIOGENESIS IN ORDER TO INTRAOPERATIVELY DEPICT TUMOR  
PERIPHERIES

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Assistant Commissioner for Patents  
Washington, D. C. 20231

**RECEIVED**

SEP 09 2002

Sir:

**TECH CENTER 1600/2900**

**CITED MATERIALS**

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_\_; see 37 C.F.R. § 1.98(d).
- ☒ Copies of materials listed but not attached were cited in an International Search Report dated August 19, 2000; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed August 6, 2002.

**LANGUAGE**

- ☐ All listed materials are in the English language; see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
- ☐ The reference(s): \_\_\_\_\_ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): \_\_\_\_\_, respectively.
- ☐ (An) English-language translation(s) of the references: \_\_\_\_\_ is (are) provided.
- ☐ A commercial English-language abstract of reference(s) \_\_\_\_\_ is (are) provided.

- ☐ An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

#### FEES

- ☒ No fee is required for this Information Disclosure Statement because:
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
- ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
- ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
- ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
- ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
- ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.


#### CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$ \_\_\_\_\_. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



James E. Ruland (Reg. No. 37,432)  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: **SCH 1869**

Date: **September 6, 2002**

JER:lvb  
K:\Sch\1869\IDS 9-6-02.doc

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

---

2**Complete if Known**

Application Number

10/088,866

Filing Date

July 2, 2002

First Named Inventor

Michael SCHIRNER et al.

Group Art Unit

1641

Examiner Name

UNASSIGNED

Attorney Docket Number

SCH 1869

## U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

~~SEP 09 2002~~

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature


Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/088,866
Filing Date	July 2, 2002
First Named Inventor	Michael SCHIRNER et al.
Group Art Unit	1641
Examiner Name	UNASSIGNED
Attorney Docket Number	SCH 1869

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		International Search Report	
		Neri Dario et al., "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform", Nature Biotechnology, Bd. 15, Nr. 12, 1997, Seiten. 1271-1275, XP002124779	
		Zusammenfassung, Seite 1271, Spalte 2, Absatz 2 - Seite 1273, Spalte 1, Absatz 5, Seite 1273, Spalte 2, Absatz 4 - Seite 1274, Absatz 1, Seite 1274, Spalte 2, letzter Absatz - Seite 1275, Spalte 1, Absatz 1	
		Viti F. et al., "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis", Cancer Research, (1999 Jan 15) 59 (2) 347-52 XP002124782	
		Zusammenfassung Abbildung 4, Seite 351, Spalte 1, letzter Absatz - Spalte 2, Absatz 1	
		Mariani G. et al., "Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants", Cancer (1997 Dec 15) 80 (12 Suppl) 2378-84 XP000960444	
		Castellani P. et al., "The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis published erratum appears in Int J. Cancer 1995 Jul 4; 62(1):118!", International Journal of Cancer (1994 Dec 1) 59 (5) 612-8, XP000960445	
		Poon et al., "Laser-induced fluorescence: experimental intraoperative delineation of tumor resection margins", STN Caplus, XX,XX, Bd. 25, Nr. 116, 22 Juni 1992 (1992-06-22), XP002076252 Zusammenfassung	
		Seite 2378, Spalte 2, Zeile 1 - Seite 2379, Spalte 1, Absatz 4, Seite 2379, Spalte 2, letzter Absatz - Seite 2380, Spalte 1, Absatz 1, Seite 2381, Spalte 1, letzter Absatz - Seite 2383, Spalte 1, Absatz 1	
		Seite 612, Spalte 2, Absatz 3, Seite 614, Spalte 1, Absatz 2 - Spalte 2, Absatz 1, Seite 616, Spalte 1, Absatz 3 - Spalte 2, Absatz 2	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JER:lvb

K:\Sch\1869\pto-1449 9-6-02.dot

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900